DDR only reviews R01 grant applications. R21 and R03 applications that address DDR guidelines will be reviewed in a Special Emphasis Panel; IDM (82).

 

The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.

Review Dates

Membership Panel

The membership panel is a list of chartered members only.

Topics


  • Anti-infective drug discovery: drug target identification, characterization and validation; novel screening methods and assay development; molecular and medicinal chemical characterization of inhibitors; structure-guided drug design; preclinical studies using animal models
  • Antimicrobial resistance: mechanisms and regulation of antimicrobial resistance; emergence, dissemination, and maintenance of resistance; strategies for the prevention of resistance; molecular characterization of resistant pathogens

Overlaps with Closely Related Study Sections

There are shared interests with Synthetic and Biological Chemistry A Study Section (SBCA) and Synthetic and Biological Chemistry B Study Section (SBCB) in the area of anti-infective drug development. Grant applications focused on the syntheses of small molecules or natural products with limited biological assessments may be reviewed in SBCA or SBCB. Applications involving some synthesis but more focused on the preclinical biological characterization of leads may be reviewed in DDR.

There are shared interests with High-Throughput Screening Special Emphasis Panel (ZRG1 BST (55)) in the area of anti-infective drug discovery and development. Grant applications that focus on developing novel high throughput screens for small molecule hits and immunotherapeutics may be reviewed in BST (55). Applications that focus on identifying anti-infective targets, molecular mechanisms of action, and the development of lead compounds for anti-infective therapeutics may be reviewed in DDR.

There are shared interests with Bacterial Pathogenesis (BACP), Host Interactions with Bacterial Pathogens (HIBP), Clinical Research and Field Studies of Infectious Diseases (CRFS), Pathogenic Eukaryotes Study Section (PTHE), and Virology A (VIRA) & Virology B (VIRB) in the area of antibacterial, antiparasitic, antifungal and antiviral drug development. Grant applications focused on the pathogenesis of bacteria, eukaryotic pathogens, or viruses, using known drugs or molecular probes may be reviewed in these panels. Applications that focus on the treatment of these pathogens may be reviewed in DDR.

There are shared interests with Prokaryotic Cell and Molecular Biology Study Section (PCMB) in the area of antibacterial strategies. Grant applications that focus on molecular mechanisms of potential bacterial drug targets may be reviewed in PCMB. Applications that focus on the development of antibacterial drugs may be reviewed in DDR.

There are shared interests with Oral, Dental and Craniofacial Sciences Study Section (ODCS) in the investigation of prevention and treatment of infectious diseases. Grant applications that focus on identification and validation of drug targets against oral bacteria may be reviewed in ODCS. Applications that focus on antibacterial drug discovery may be reviewed in DDR.